Login
$GOSS
$10.98 +$0.01 (0.09%) Live

$GOSS 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

– New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 –

28 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast for or against, the ...

28 Sep 2026 8-K: Other Events

On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price ...

23 Sep 2026 8-K: Other Events

On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arteri...

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hype...

11 Sep 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

SAN DIEGO—(BUSINESS WIRE)— September 11, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment...

09 Sep 2026 8-K: Other Events

SAN DIEGO—(BUSINESS WIRE)— September 9, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment ...

03 Sep 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

The registered office of Gossamer Bio, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended and/or restated from time to time (the “certificate of incorporation”).

26 Aug 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Gossamer Bio, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”), does hereby certify that, in accordance with Sections 141(c) and 151 o...

21 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This Securities Purchase Agreement (the “Agreement”) is made as of August 20, 2026 (the “Effective Date”), by and among Gossamer Bio, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set fort...

13 Aug 2026 8-K: Results of Operations and Financial Condition

- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes -

27 Jul 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

This RIGHTS REACQUISITION AGREEMENT (this “Agreement”) is entered into as of July 23, 2026 (the “Rights Reacquisition Effective Date”), by and among Chiesi Farmaceutici S.p.A., a corporation incorporated under the laws of Italy (“Chiesi ...

15 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

GOSSAMER BIO, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective May 18, 2026) ARTICLE I. PURPOSE The purpose of this amended and restated Plan is to enhance the Company’s ability to attract, retain and motivate persons wh...

01 Jul 2026 8-K: Regulation FD Disclosure

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

17 Jun 2026 8-K: Regulation FD Disclosure

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

05 Jun 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

Exhibit 10.1 GOSSAMER BIO, INC., THE GUARANTORS PARTY HERETO FROM TIME TO TIME, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent INDENTURE Dated as of June 4...

05 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as appl...

02 Jun 2026 8-K: Other Events

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

18 May 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more

This TRANSACTION SUPPORT AGREEMENT (together with all exhibits and attachments hereto, as amended, supplemented, or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of May 18, 2026, is...

09 Apr 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On April 8, 2026, Gossamer Bio, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutiv...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support